Epilepsy is the fourth most common neurological disorder, but current treatment options
provide limited efficacy and carry the potential for problematic adverse effects. There is an …

The intralaminar thalamus, in particular the centromedian-parafascicular complex, forms a
strategic node between ascending information from the spinal cord and brainstem and …

Advances in technologies that can record and stimulate deep brain activity in humans have
led to impactful discoveries within the field of neuroscience and contributed to the …

Introduction Neurostimulation applied from deep brain stimulation (DBS) electrodes is an
effective therapeutic intervention in patients suffering from intractable drug-resistant epilepsy …

OBJECTIVE Neuromodulation of the centromedian nucleus of the thalamus (CM) has
unclear effectiveness in the treatment of drug-resistant epilepsy. Prior reports suggest that it …

Deep brain stimulation (DBS), specifically thalamic DBS, has achieved promising results to
reduce seizure severity and frequency in pharmacoresistant epilepsies, thereby establishing …

Up to 20% of pediatric patients with primary generalized epilepsy (PGE) will not respond
effectively to medication for seizure control. Responsive neurostimulation (RNS) is a …

Epilepsy affects approximately 70 million people worldwide, and it is a significant contributor
to the global burden of neurological disorders. Despite the advent of new AEDs, drug …

Vagus nerve stimulation (VNS) Therapy® is an adjunctive neurostimulation treatment for
people with drug-resistant epilepsy (DRE) who are unwilling to undergo resective surgery …

Alzheimer's disease (AD) patients have a high risk of develo** mesial temporal lobe
epilepsy (MTLE) and subclinical epileptiform activity. MTLE in AD worsens outcomes …